Results 271 to 280 of about 382,920 (355)

Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results. [PDF]

PLoS One
Rjoop A, Perez I, Al Aruri DO, AlBarakat MM, van Rhee F, Drobena G.   +5 more
europepmc   +1 more source

European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma

Paula Rodriguez-Otero, Philippe moreau, María-Victoria Mateos, Maria Theresa Krauth, Leo Rasche, Efstathios Kastritis, Albert Oriol, Elena Zamagni, Claire Albrecht, Eva Rubio-Azpeitia, Niels van de Donk   +10 more
openalex   +1 more source

Cesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement

British Journal of Haematology, EarlyView.
ARI0002h induced response in 15/17 patients with plasma cell leukaemia (PCL)/central nervous system (CNS)‐multiple myeloma (MM) (87% achieved ≥ very good partial response [VGPR]) with a median progression‐free survival (PFS)/overall survival (OS) of 10.5 and 15.9 months respectively.
Carlos Jimenez‐Mira, Natalia Tovar, Núria Martínez‐Cibrián, Verónica González‐Calle, Nil Albiol, Nieves López‐Muñoz, Aina Oliver‐Caldés, Azucena González, José Miguel Mateos, Marta Español‐Rego, Laura Rosiñol, Manel Juan, Paola Charry, José María Sanchez‐Pina, Sergio Navarro, Daniel Munárriz, Lucía López‐Corral, Valentín Ortiz‐Maldonado, Sara Varea, Eulalia Olesti, Julio Delgado, Álvaro Urbano‐Ispizua, Joaquín Martínez‐López, María Victoria Mateos, Luis Gerardo Rodríguez‐Lobato, Carlos Fernández de Larrea   +25 more
wiley   +1 more source

Fiber intake associates with increased treatment response in patients with multiple myeloma along with changes in gut microbiome. [PDF]

Blood Adv
Sester LS, Galeeva I, de Castilhos J, Borisov V, Gambihler AK, Kilian M, Vonhören D, Friedrich MJ, Poschet G, Steiger S, Chechenina A, Lettau K, Kohlberger CP, Prokoph N, Frenking J, John L, Huhn S, Reichert P, Mai EK, Rippe K, Sauer S, Müller-Tidow C, Weinhold N, Platten M, Goldschmidt H, Raab MS, Stein-Thoeringer CK.   +26 more
europepmc   +1 more source

Diffuse Hepatic, Splenic, and Osseous Activity Due to Multiple Myeloma. [PDF]

Clin Nucl Med
Zhao X, Liang H, Zhao G, Wei L, Xie P.
europepmc   +1 more source

Knowledge, attitudes, and practices of patients with multiple myeloma regarding venous thromboembolism: a cross-sectional study. [PDF]

Front Cardiovasc Med
Zhang R, Weng Y, Wu S, Liao T, Pan P, Gou H, Ding W, Dong M, Yang Z.   +8 more
europepmc   +1 more source

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

British Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall, James Croft, Katrina Walker, Kevin Boyd, Sadie Roberts, Amy Holroyd, Mamta Garg, Elsa Ferris, Gordon Cook, William E. Pierceall, Anjan Thakurta, Anita Gandhi, Charlotte Pawlyn, Sarah R. Brown, Martin Kaiser   +14 more
wiley   +1 more source

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

, 2017
D Bhutani, Zonder JA
openalex   +1 more source

Acute septic arthritis of the ankle in an immunocompromised patient with multiple myeloma: a case report. [PDF]

Ann Med Surg (Lond)
Haribat AI, Sadeh M, Abuzahra M, Salhab Z, Hasani A, Abed A, Abuzahra T, Aladra M.   +7 more
europepmc   +1 more source